Fiche société
Beijing Tsinghua Chang Gung Hospital
Traitements, essais et publications liés.
Traitements2programmes
Essais2liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CD19/CD20 Dual-CAR-T cellsThis is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory or relapsed B-NHL. | SEP | Phase 1 | Immunomodulation + Thérapie cellulaire | China | À vérifier |
| CD19/CD20 Dual-CAR-T cellsThis is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory or relapsed B-NHL. | SEP | Phase 1 | Immunomodulation + Thérapie cellulaire | China | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Vericiguat | Insuffisance cardiaque | À vérifier | NCT07877831 | Vericiguat Use and Incident Atrial Fibrillation in Chronic Heart Failure | ACTIVE_NOT_RECRUITING |
| CD19/CD20 Dual-CAR-T cells | SEP | Phase 1 | NCT04697290 | CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. | SUSPENDED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||